Abstract
Objectives To examine disparities in mental health diagnosis, depression screening, and depressive symptoms in pediatric primary care settings before and during the COVID-19 pandemic, and to evaluate the use of electronic health records to study temporal trends in pediatric mental and behavioral health (MBH).
Methods This is an IRB-approved, retrospective study of pediatric patients (n=10,866) who visited three primary care sites at an academic medical center before (2017-2019) and during (2020-2022) the COVID-19 pandemic. We used logistic regression to compare rates of diagnoses, depression screening, and depression symptom scores among demographic groups.
Results This study demonstrates an increase in both PHQ-9A screening rates and average scores from 2017-2019 to 2020-2022. There were significant disparities in common mental health diagnoses, including higher rates of psychological distress among lower income and Hispanic patients, both before and during the pandemic, despite lower rates of screening among Hispanic patients. This suggests a need for improved equity in routine MBH screening and additional research to better understand the underlying social determinants that may be driving the greater mental health burden for certain marginalized youth.
This study also highlights the strengths and challenges of utilizing EHR data to characterize disparities in pediatric mental illness. Although the nature of care delivery in an academic medical center clinic and the limitations of the EHR for collecting relevant data present challenges to this measurement, the EHR is nevertheless a promising tool for measuring and tracking pediatric mental health disparities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work of Irene Mathieu was conducted with the support of the iTHRIV Scholars Program. The iTHRIV Scholars Program is supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health under award numbers UL1TR003015 and KL2TR003016 as well as by the University of Virginia. This content is solely the responsibility of the authors and does not necessarily represent the official views of NIH or the University of Virginia.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was approved by the University of Virginia Institutional Review Board for Health Sciences Research as an exempt study and has granted a waiver of HIPAA authorization under 45CFR 164.512(i)(2) via expedited review procedures for the main study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Research data are not shared.
